Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMFGMD9)

• Drug Name: LUBELUZOLE Drug Info
• Synonyms: Lubeluzole; Prosynap; 144665-07-6; UNII-V2SIB71583; CHEMBL281724; V2SIB71583; R 87926; R-87926; (2S)-1-[4-[1,3-benzothiazol-2-yl(methyl)amino]piperidin-1-yl]-3-(3,4-difluorophenoxy)propan-2-ol; (+)-(S)-4-(2-Benzothiazolylmethylamino)-alpha-((3,4-difluorophenoxy)methyl)-1-piperidineethanol; 1-Piperidineethanol, 4-(2-benzothiazolylmethylamino)-alpha-((3,4-difluorophenoxy)methyl)-, (S)-; Lubeluzol; Lubeluzole [USAN:INN:BAN]; C22H25F2N3O2S; Prosynap (TN); R-91154; AC1Q4ONU; Lubeluzole (USAN/INN); SCHEMBL159725; Lubeluzole [USAN:B

Indication

Disease Entry	ICD 11	Status	REF
Neurological disorder	6B60	Discontinued in Preregistration	[1]

• Cross-matching ID:
  PubChem CID: 65998
  ChEBI ID: CHEBI:135703
  CAS Number: CAS 144665-07-6
  TTD Drug ID: DMFGMD9

Molecule-Related Drug Atlas

Drug(s) Targeting Sodium channel unspecific (NaC)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Phenytoin	DMNOKBV	Epilepsy	8A60-8A68	Approved	[3]
Carbamazepine	DMZOLBI	Epilepsy	8A60-8A68	Approved	[4]
Zonisamide	DM0DTF7	Alcohol dependence	6C40.2	Approved	[5]
Eslicarbazepine	DMZREFQ	Seizure disorder	8A6Z	Approved	[6]
LIDOFLAZINE	DMV23GL	Angina pectoris	BA40	Approved	[7]
LOMERIZINE	DME0TC8	Migraine	8A80	Approved	[2]
Levobupivacaine	DM783CH	Anaesthesia	9A78.6	Approved	[8]
Tetrodotoxin	DMWMPRG	Bacterial infection	1A00-1C4Z	Approved	[9]
Permethrin	DMZ0Q1G	Pediculus capitis infestation	1G00.0	Approved	[10]
Rufinamide	DMWE60C	Epilepsy	8A60-8A68	Approved	[11]

Drug(s) Targeting Voltage-gated sodium channel alpha Nav1.5 (SCN5A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Mephenytoin	DM5UGDK	Epilepsy	8A60-8A68	Approved	[3]
Mexiletine	DMCTE9R	Ventricular tachycardia	BC71	Approved	[12]
Fosphenytoin	DMOX3LB	Epilepsy	8A60-8A68	Approved	[3]
Disopyramide	DM5SYZP	Long QT syndrome	BC65.0	Approved	[12]
LOMERIZINE	DME0TC8	Migraine	8A80	Approved	[2]
Tetrodotoxin	DMWMPRG	Bacterial infection	1A00-1C4Z	Approved	[13]
Dyclonine	DMU6OFP	Pain	MG30-MG3Z	Approved	[14]
Moricizine	DMOMBJW	Arrhythmia	BC9Z	Approved	[15]
Ethotoin	DMXWOCP	Complex partial seizure	8A68.0	Approved	[16]
Prilocaine	DMI7DZ2	Pain	MG30-MG3Z	Approved	[14]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Sodium channel unspecific (NaC)	TTRK8B9	NOUNIPROTAC	Inhibitor	[2]
Voltage-gated sodium channel alpha Nav1.5 (SCN5A)	TTZOVE0	SCN5A_HUMAN	Inhibitor	[2]

References

• [1] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005388)
• [2] Medicinal chemistry of neuronal voltage-gated sodium channel blockers. J Med Chem. 2001 Jan 18;44(2):115-37.
• [3] Lacosamide: a new approach to target voltage-gated sodium currents in epileptic disorders. CNS Drugs. 2009;23(7):555-68.
• [4] Sidedness of carbamazepine accessibility to voltage-gated sodium channels. Mol Pharmacol. 2014 Feb;85(2):381-7.
• [5] Antiepileptic drugs and relapse after epilepsy surgery. Epileptic Disord. 2008 Sep;10(3):193-8.
• [6] Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX). Epilepsy Res. 2009 Jan;83(1):1-43.
• [7] Synthesis and pharmacological evaluation of phenylacetamides as sodium-channel blockers. J Med Chem. 1994 Jan 21;37(2):268-74.
• [8] Block of neuronal tetrodotoxin-resistant Na+ currents by stereoisomers of piperidine local anesthetics. Anesth Analg. 2000 Dec;91(6):1499-505.
• [9] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [10] In vitro assays for repellents and deterrents for ticks: differing effects of products when tested with attractant or arrestment stimuli. Med Vet Entomol. 2003 Dec;17(4):370-8.
• [11] Emerging drugs for epilepsy. Expert Opin Emerg Drugs. 2007 Sep;12(3):407-22.
• [12] Effect of sodium channel blockers on ST segment, QRS duration, and corrected QT interval in patients with Brugada syndrome. J Cardiovasc Electrophysiol. 2000 Dec;11(12):1320-9.
• [13] Halothane attenuates the cerebroprotective action of several Na+ and Ca2+ channel blockers via reversal of their ion channel blockade. Eur J Pharmacol. 2002 Oct 4;452(2):175-81.
• [14] Monoamine transporter and sodium channel mechanisms in the rapid pressor response to cocaine. Pharmacol Biochem Behav. 1998 Feb;59(2):305-12.
• [15] From first class to third class: recent upheaval in antiarrhythmic therapy--lessons from clinical trials. Am J Cardiol. 1996 Aug 29;78(4A):28-33.
• [16] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.